Figure 5
From: Inhibition of bone morphogenetic protein 6 receptors ameliorates Sjögren’s syndrome in mice
pSMAD1/5/8 and ID3 expression in submandibular glands of C57BL/6.NOD-Aec1Aec2 mice after ALK2/3 inhibitor treatment. Confocal images demonstrating expression of pSMAD1/5/8 and ID3 in submandibular glands (SMGs) of LDN-treated C57BL/6.NOD-Aec1Aec2 mice. (A) Representative images of pSMAD1/5/8 and ID3 expression in SMGs of mice daily treated with PBS (control, left panels), 2.5 mg/kg LDN-212854 (middle panels), or 2.5 mg/kg LDN-193189 (right panels) for 24 days. Row 1 & 3: slides labeled with pSMAD1/5/8 and ID3 antibodies, respectively (40× objective, white bar: 50 µm). Row 2 & 4: Inset for the marked area in row 1 and 3, respectively (red-dashed box). (B,C) Statistical analysis showed a significant decrease in (B) pSMAD1/5/8 and (C) ID3 expression in LDN-treated mice compared with PBS-treated (control) mice (P < 0.05). Data shown are means ± SEM from N ≥3 mice respectively. Statistical significance was determined with unpaired Student’s t test.
